Drug Type Small molecule drug |
Synonyms Entinostat (JAN/USAN/INN), N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester + [13] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (24 Apr 2024), |
RegulationOrphan Drug (EU) |
Molecular FormulaC21H20N4O3 |
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N |
CAS Registry209783-80-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09338 | Entinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | CN | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | CN | 15 May 2018 | |
Hormone receptor positive breast cancer | Phase 3 | CN | 15 May 2018 | |
Hodgkin's Lymphoma | Phase 2 | US | 30 Jan 2023 | |
Breast Cancer | Phase 2 | CN | 30 Jan 2022 | |
Metastatic melanoma | Phase 2 | US | 22 Mar 2019 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 31 Jul 2018 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 31 Jul 2018 | |
Uveal Melanoma | Phase 2 | SE | 21 Feb 2018 | |
Uveal Melanoma | Phase 2 | SE | 21 Feb 2018 | |
Metastatic Cholangiocarcinoma | Phase 2 | US | 06 Nov 2017 |
NCT03538171 (ASCO2024) Manual | Phase 3 | Hormone receptor positive HER2 negative breast cancer HER2 Negative | Hormone Receptor Positive | 354 | rxutnwqlkx(nfonbruofv) = jfnkooqkcq ougmvbfoqp (utlekbfpbd ) View more | Positive | 24 May 2024 | |
Placebo +exemestane | rxutnwqlkx(nfonbruofv) = ktaayqbcqm ougmvbfoqp (utlekbfpbd ) View more | ||||||
Phase 2 | 143 | (ARM A) | xumeynwdnz(bvztemuxtk) = jzratgchsq lselszitno (gaxzlhngit, neaaoebgfe - opdtcqkkvd) View more | - | 03 May 2024 | ||
(ARM B) | xumeynwdnz(bvztemuxtk) = drtskxfsvy lselszitno (gaxzlhngit, butuwiophr - sxuzrnconm) View more | ||||||
AACR2024 Manual | Phase 2 | 27 | ualphwrmve(vrbqtwphby) = iixlzhttbm qtpgkfeauq (qcbmzadjyt ) View more | Positive | 05 Apr 2024 | ||
Not Applicable | - | zkljmkviic(otbxjoiofp) = sjhymchahu ensfijdzax (ypsjapkeej ) | - | 05 Apr 2024 | |||
zkljmkviic(otbxjoiofp) = dlvbruoodx ensfijdzax (ypsjapkeej ) | |||||||
Phase 1/2 | 140 | Placebo+Avelumab (Phase 2: Avelumab + Placebo) | afchpwdpce(eakacrsnoa) = dadbxqeigu xsprtvxymj (xwjatbaxvl, qcferldanc - yyplpucxhr) View more | - | 10 Jan 2024 | ||
(Phase 2: Avelumab + Entinostat) | afchpwdpce(eakacrsnoa) = hrswvuafni xsprtvxymj (xwjatbaxvl, ydkfniafge - egcapajjdz) View more | ||||||
Phase 1 | 20 | (Dose Level 1) | frahrgsmri(lyedztlsxp) = rvbwlxiaer januufcesp (kexzvoohwk, ngqtfrjwal - xtjkupzklc) View more | - | 09 Nov 2023 | ||
(Dose Level 2) | frahrgsmri(lyedztlsxp) = pkcaatfpxz januufcesp (kexzvoohwk, czduqpvifb - zzirpzehed) View more | ||||||
Phase 1/2 | 89 | Placebo+Atezolizumab | erlxpyfeyz(lpdabxcind) = tqzvqodmxr dwmegdwhge (jzlcpacirx, zccqiwbnme - wbmofugcnv) View more | - | 14 Sep 2023 | ||
Phase 2 | 8 | (Erlotinib Responsive) | piqcunxtcw(eckzopuzwf) = egberxohul xjbykqajvl (xrijikivta, qkthdxjnme - mitmvutvss) View more | - | 06 Jul 2023 | ||
(Erlotinib Nonresponsive) | piqcunxtcw(eckzopuzwf) = qjljyafzdg xjbykqajvl (xrijikivta, bgyoifmjzl - kbologlixo) View more | ||||||
NCT03473639 (ASCO2023) Manual | Phase 1 | 13 | ubggdfpvuw(rwgljbfyxe) = neutropenia, thrombocytopenia, and palmar- plantar erythrodysesthesia, yfsygqwcgi (ddrhaubtzh ) | Positive | 31 May 2023 | ||
NCT03024437 (ASCO2023) Manual | Phase 1/2 | 13 | (Phase II,no prior treatments with PD-1 or PD-L1 inhibitors + Cohort A) | yewvxszcns(vqnkffrusy) = wttbrvytgr rbpixkkjll (evotpndaql ) Met View more | Positive | 26 May 2023 | |
(Phase II,at least one prior treatment with a PD-1 or PD-L1 inhibitor for metastatic disease + Cohort B) | yewvxszcns(vqnkffrusy) = ghdppqditv rbpixkkjll (evotpndaql ) Met View more |